Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Aug 1;357(Pt 3):859–865. doi: 10.1042/0264-6021:3570859

Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor.

R J Raggers 1, I Vogels 1, G van Meer 1
PMCID: PMC1222017  PMID: 11463358

Abstract

The human multidrug-resistance (MDR1) P-glycoprotein (Pgp) is an ATP-binding-cassette transporter (ABCB1) that is ubiquitously expressed. Often its concentration is high in the plasma membrane of cancer cells, where it causes multidrug resistance by pumping lipophilic drugs out of the cell. In addition, MDR1 Pgp can transport analogues of membrane lipids with shortened acyl chains across the plasma membrane. We studied a role for MDR1 Pgp in transport to the cell surface of the signal-transduction molecule platelet-activating factor (PAF). PAF is the natural short-chain phospholipid 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine. [(14)C]PAF synthesized intracellularly from exogenous alkylacetylglycerol and [(14)C]choline became accessible to albumin in the extracellular medium of pig kidney epithelial LLC-PK1 cells in the absence of vesicular transport. Its translocation across the apical membrane was greatly stimulated by the expression of MDR1 Pgp, and inhibited by the MDR1 inhibitors PSC833 and cyclosporin A. Basolateral translocation was not stimulated by expression of the basolateral drug transporter MRP1 (ABCC1). It was insensitive to the MRP1 inhibitor indomethacin and to depletion of GSH which is required for MRP1 activity. While efficient transport of PAF across the apical plasma membrane may be physiologically relevant in MDR1-expressing epithelia, PAF secretion in multidrug-resistant tumours may stimulate angiogenesis and thereby tumour growth.

Full Text

The Full Text of this article is available as a PDF (157.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson B. O., Bensard D. D., Harken A. H. The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet. 1991 May;172(5):415–424. [PubMed] [Google Scholar]
  2. Andrick C., Bröring K., Deuticke B., Haest C. W. Fast translocation of phosphatidylcholine to the outer membrane leaflet after its synthesis at the inner membrane surface in human erythrocytes. Biochim Biophys Acta. 1991 May 7;1064(2):235–241. doi: 10.1016/0005-2736(91)90307-t. [DOI] [PubMed] [Google Scholar]
  3. Billah M. M., Johnston J. M. Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. Biochem Biophys Res Commun. 1983 May 31;113(1):51–58. doi: 10.1016/0006-291x(83)90430-8. [DOI] [PubMed] [Google Scholar]
  4. Blank M. L., Snyder F., Byers L. W., Brooks B., Muirhead E. E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun. 1979 Oct 29;90(4):1194–1200. doi: 10.1016/0006-291x(79)91163-x. [DOI] [PubMed] [Google Scholar]
  5. Boesch D., Gavériaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991 Aug 15;51(16):4226–4233. [PubMed] [Google Scholar]
  6. Bosch I., Dunussi-Joannopoulos K., Wu R. L., Furlong S. T., Croop J. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry. 1997 May 13;36(19):5685–5694. doi: 10.1021/bi962728r. [DOI] [PubMed] [Google Scholar]
  7. Bratton D. L. Release of platelet activation factor from activated neutrophils. Transglutaminase-dependent enhancement of transbilayer movement across the plasma membrane. J Biol Chem. 1993 Feb 15;268(5):3364–3373. [PubMed] [Google Scholar]
  8. Camussi G., Aglietta M., Malavasi F., Tetta C., Piacibello W., Sanavio F., Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. J Immunol. 1983 Nov;131(5):2397–2403. [PubMed] [Google Scholar]
  9. Camussi G., Pawlowski I., Bussolino F., Caldwell P. R., Brentjens J., Andres G. Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells. J Immunol. 1983 Oct;131(4):1802–1807. [PubMed] [Google Scholar]
  10. Cox C. P., Wardlow M. L., Jorgensen R., Farr R. S. The presence of platelet-activating factor (PAF) in normal human mixed saliva. J Immunol. 1981 Jul;127(1):46–50. [PubMed] [Google Scholar]
  11. Dekkers D. W., Comfurius P., Schroit A. J., Bevers E. M., Zwaal R. F. Transbilayer movement of NBD-labeled phospholipids in red blood cell membranes: outward-directed transport by the multidrug resistance protein 1 (MRP1). Biochemistry. 1998 Oct 20;37(42):14833–14837. doi: 10.1021/bi981011w. [DOI] [PubMed] [Google Scholar]
  12. Dekkers D. W., Comfurius P., van Gool R. G., Bevers E. M., Zwaal R. F. Multidrug resistance protein 1 regulates lipid asymmetry in erythrocyte membranes. Biochem J. 2000 Sep 1;350(Pt 2):531–535. [PMC free article] [PubMed] [Google Scholar]
  13. Dentan C., Tselepis A. D., Chapman M. J., Ninio E. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta. 1996 Feb 16;1299(3):353–357. doi: 10.1016/0005-2760(95)00226-x. [DOI] [PubMed] [Google Scholar]
  14. Derewenda Z. S., Ho Y. S. PAF-acetylhydrolases. Biochim Biophys Acta. 1999 Nov 23;1441(2-3):229–236. doi: 10.1016/s1388-1981(99)00158-4. [DOI] [PubMed] [Google Scholar]
  15. Ernest S., Bello-Reuss E. Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J Am Soc Nephrol. 1999 Nov;10(11):2306–2313. doi: 10.1681/ASN.V10112306. [DOI] [PubMed] [Google Scholar]
  16. Evers R., Zaman G. J., van Deemter L., Jansen H., Calafat J., Oomen L. C., Oude Elferink R. P., Borst P., Schinkel A. H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest. 1996 Mar 1;97(5):1211–1218. doi: 10.1172/JCI118535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Germann U. A., Chambers T. C., Ambudkar S. V., Licht T., Cardarelli C. O., Pastan I., Gottesman M. M. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem. 1996 Jan 19;271(3):1708–1716. doi: 10.1074/jbc.271.3.1708. [DOI] [PubMed] [Google Scholar]
  18. Grant C. E., Valdimarsson G., Hipfner D. R., Almquist K. C., Cole S. P., Deeley R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994 Jan 15;54(2):357–361. [PubMed] [Google Scholar]
  19. Higgins C. F. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113. doi: 10.1146/annurev.cb.08.110192.000435. [DOI] [PubMed] [Google Scholar]
  20. Higgins C. F., Gottesman M. M. Is the multidrug transporter a flippase? Trends Biochem Sci. 1992 Jan;17(1):18–21. doi: 10.1016/0968-0004(92)90419-a. [DOI] [PubMed] [Google Scholar]
  21. Klausner R. D., Donaldson J. G., Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol. 1992 Mar;116(5):1071–1080. doi: 10.1083/jcb.116.5.1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Madden M. C., Smith J. P., Dailey L. A., Friedman M. Polarized release of lipid mediators derived from phospholipase A2 activity in a human bronchial cell line. Prostaglandins. 1994 Sep;48(3):197–215. doi: 10.1016/0090-6980(94)90019-1. [DOI] [PubMed] [Google Scholar]
  23. Marcheselli V. L., Rossowska M. J., Domingo M. T., Braquet P., Bazan N. G. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J Biol Chem. 1990 Jun 5;265(16):9140–9145. [PubMed] [Google Scholar]
  24. Mechetner E., Kyshtoobayeva A., Zonis S., Kim H., Stroup R., Garcia R., Parker R. J., Fruehauf J. P. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res. 1998 Feb;4(2):389–398. [PubMed] [Google Scholar]
  25. Montrucchio G., Sapino A., Bussolati B., Ghisolfi G., Rizea-Savu S., Silvestro L., Lupia E., Camussi G. Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol. 1998 Nov;153(5):1589–1596. doi: 10.1016/S0002-9440(10)65747-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Panwala C. M., Jones J. C., Viney J. L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998 Nov 15;161(10):5733–5744. [PubMed] [Google Scholar]
  27. Prescott S. M., Zimmerman G. A., Stafforini D. M., McIntyre T. M. Platelet-activating factor and related lipid mediators. Annu Rev Biochem. 2000;69:419–445. doi: 10.1146/annurev.biochem.69.1.419. [DOI] [PubMed] [Google Scholar]
  28. Raggers R. J., Pomorski T., Holthuis J. C., Kälin N., van Meer G. Lipid traffic: the ABC of transbilayer movement. Traffic. 2000 Mar;1(3):226–234. doi: 10.1034/j.1600-0854.2000.010305.x. [DOI] [PubMed] [Google Scholar]
  29. Raggers R. J., van Helvoort A., Evers R., van Meer G. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J Cell Sci. 1999 Feb;112(Pt 3):415–422. doi: 10.1242/jcs.112.3.415. [DOI] [PubMed] [Google Scholar]
  30. Record M., Ribbes G., Tercé F., Chap H. Subcellular localization of phospholipids and enzymes involved in PAF-acether metabolism. J Cell Biochem. 1989 Jul;40(3):353–359. doi: 10.1002/jcb.240400311. [DOI] [PubMed] [Google Scholar]
  31. Ruetz S., Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell. 1994 Jul 1;77(7):1071–1081. doi: 10.1016/0092-8674(94)90446-4. [DOI] [PubMed] [Google Scholar]
  32. Schinkel A. H., Wagenaar E., van Deemter L., Mol C. A., Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698–1705. doi: 10.1172/JCI118214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schneider E., Haest C. W., Deuticke B. Transbilayer reorientation of platelet-activating factor in the erythrocyte membrane. FEBS Lett. 1986 Mar 31;198(2):311–314. doi: 10.1016/0014-5793(86)80427-6. [DOI] [PubMed] [Google Scholar]
  34. Shiao Y. J., Vance J. E. Sphingomyelin transport to the cell surface occurs independently of protein secretion in rat hepatocytes. J Biol Chem. 1993 Dec 15;268(35):26085–26092. [PubMed] [Google Scholar]
  35. Smit J. J., Schinkel A. H., Oude Elferink R. P., Groen A. K., Wagenaar E., van Deemter L., Mol C. A., Ottenhoff R., van der Lugt N. M., van Roon M. A. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993 Nov 5;75(3):451–462. doi: 10.1016/0092-8674(93)90380-9. [DOI] [PubMed] [Google Scholar]
  36. Smith A. J., Timmermans-Hereijgers J. L., Roelofsen B., Wirtz K. W., van Blitterswijk W. J., Smit J. J., Schinkel A. H., Borst P. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett. 1994 Nov 14;354(3):263–266. doi: 10.1016/0014-5793(94)01135-4. [DOI] [PubMed] [Google Scholar]
  37. Smith A. J., van Helvoort A., van Meer G., Szabo K., Welker E., Szakacs G., Varadi A., Sarkadi B., Borst P. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530–23539. doi: 10.1074/jbc.M909002199. [DOI] [PubMed] [Google Scholar]
  38. Szabó K., Bakos E., Welker E., Müller M., Goodfellow H. R., Higgins C. F., Váradi A., Sarkadi B. Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity. J Biol Chem. 1997 Sep 12;272(37):23165–23171. doi: 10.1074/jbc.272.37.23165. [DOI] [PubMed] [Google Scholar]
  39. Triggiani M., Schleimer R. P., Tomioka K., Hubbard W. C., Chilton F. H. Characterization of platelet-activating factor synthesized by normal and granulocyte-macrophage colony-stimulating factor-primed human eosinophils. Immunology. 1992 Dec;77(4):500–504. [PMC free article] [PubMed] [Google Scholar]
  40. Twentyman P. R., Bleehen N. M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer. 1991;27(12):1639–1642. doi: 10.1016/0277-5379(91)90435-g. [DOI] [PubMed] [Google Scholar]
  41. Vallari D. S., Record M., Snyder F. Conversion of alkylacetylglycerol to platelet-activating factor in HL-60 cells and subcellular localization of the mediator. Arch Biochem Biophys. 1990 Feb 1;276(2):538–545. doi: 10.1016/0003-9861(90)90756-o. [DOI] [PubMed] [Google Scholar]
  42. Woodard D. S., Lee T. C., Snyder F. The final step in the de novo biosynthesis of platelet-activating factor. Properties of a unique CDP-choline:1-alkyl-2-acetyl-sn-glycerol choline-phosphotransferase in microsomes from the renal inner medulla of rats. J Biol Chem. 1987 Feb 25;262(6):2520–2527. [PubMed] [Google Scholar]
  43. van Helvoort A., Giudici M. L., Thielemans M., van Meer G. Transport of sphingomyelin to the cell surface is inhibited by brefeldin A and in mitosis, where C6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity. J Cell Sci. 1997 Jan;110(Pt 1):75–83. doi: 10.1242/jcs.110.1.75. [DOI] [PubMed] [Google Scholar]
  44. van Helvoort A., Smith A. J., Sprong H., Fritzsche I., Schinkel A. H., Borst P., van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 1996 Nov 1;87(3):507–517. doi: 10.1016/s0092-8674(00)81370-7. [DOI] [PubMed] [Google Scholar]
  45. van Helvoort A., van't Hof W., Ritsema T., Sandra A., van Meer G. Conversion of diacylglycerol to phosphatidylcholine on the basolateral surface of epithelial (Madin-Darby canine kidney) cells. Evidence for the reverse action of a sphingomyelin synthase. J Biol Chem. 1994 Jan 21;269(3):1763–1769. [PubMed] [Google Scholar]
  46. van Meer G., Op den Kamp J. A. Transbilayer movement of various phosphatidylcholine species in intact human erythrocytes. J Cell Biochem. 1982;19(2):193–204. doi: 10.1002/jcb.240190209. [DOI] [PubMed] [Google Scholar]
  47. van der Bijl P., Lopes-Cardozo M., van Meer G. Sorting of newly synthesized galactosphingolipids to the two surface domains of epithelial cells. J Cell Biol. 1996 Mar;132(5):813–821. doi: 10.1083/jcb.132.5.813. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES